Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I

被引:89
作者
Brunmair, B
Lest, A
Staniek, K
Gras, F
Scharf, N
Roden, M
Nohl, H
Waldhäusl, W
Fürnsinn, C
机构
[1] Med Univ Vienna, Dept Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria
[2] Vet Univ Vienna, A-1030 Vienna, Austria
关键词
D O I
10.1124/jpet.104.068312
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Fibrates are used for the treatment of dyslipidemia and known to affect mitochondrial function in vitro. To better understand the mechanisms underlying their mitochondrial effects, fibrate actions on complex I of the respiratory chain and cell respiration were studied in vitro. In homogenates of rat skeletal muscle, fenofibrate, and to a lesser extent clofibrate, reduced the activity of complex I (10, 30, and 100 muM fenofibrate: -41+/-7%, -70+/-2%, and -78+/-4%; 100 muM clofibrate: -27+/-7%; p<0.005 each). Inhibition of complex I by fenofibrate (100 mu M) was confirmed by reduced state 3 respiration of isolated mitochondria consuming glutamate + malate as substrates for complex I (-33 +/- 4%; p<0.0005), but not of such consuming succinate as substrate for complex II (-8+/-4%; NS). In isolated rat muscle, 24-h fenofibrate exposure (25, 50, and 100 muM) decreased CO 2 production from palmitate (-15+/-7%, -23+/-8%, and -22+/-7%; p<0.05 each) and increased lactate release (+15 +/- 5%, +14 +/- 5%, and +17 +/- 6%; p<0.02 each) indicating impaired cell respiration. Ciprofibrate and gemfibrocil (but not bezafibrate) impaired cell respiration without any inhibition of complex I. Our findings support the notion that individual fibrates induce mitochondrial dysfunction via different molecular mechanisms and show that fenofibrate predominantly acts by inhibition of complex I of the respiratory chain.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 25 条
[1]
FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA [J].
BALFOUR, JA ;
MCTAVISH, D ;
HEEL, RC .
DRUGS, 1990, 40 (02) :260-290
[2]
Thiazolidinediones, like metformin, inhibit respiratory complex I -: A common mechanism contributing to their antidiabetic actions? [J].
Brunmair, B ;
Staniek, K ;
Gras, F ;
Scharf, N ;
Althaym, A ;
Clara, R ;
Roden, M ;
Gnaiger, E ;
Nohl, H ;
Waldhäusl, W ;
Fürnsinn, C .
DIABETES, 2004, 53 (04) :1052-1059
[3]
Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression [J].
Brunmair, B ;
Gras, F ;
Neschen, S ;
Roden, M ;
Wagner, L ;
Waldhäusl, W ;
Fürnsinn, C .
DIABETES, 2001, 50 (10) :2309-2315
[4]
INSULIN RESISTANCE IN SOLEUS MUSCLE FROM OBESE ZUCKER RATS - INVOLVEMENT OF SEVERAL DEFECTIVE SITES [J].
CRETTAZ, M ;
PRENTKI, M ;
ZANINETTI, D ;
JEANRENAUD, B .
BIOCHEMICAL JOURNAL, 1980, 186 (02) :525-534
[5]
Mechanisms of disease: Mitochondrial respiratory-chain diseases [J].
DiMauro, S ;
Schon, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2656-2668
[6]
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I [J].
El-Mir, MY ;
Nogueira, V ;
Fontaine, E ;
Avéret, N ;
Rigoulet, M ;
Leverve, X .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (01) :223-228
[7]
FAILURE OF GLP-1(7-36)AMIDE TO AFFECT GLYCOGENESIS IN RAT SKELETAL-MUSCLE [J].
FURNSINN, C ;
EBNER, K ;
WALDHAUSL, W .
DIABETOLOGIA, 1995, 38 (07) :864-867
[8]
The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk [J].
Ginsberg, HN ;
Stalenhoef, AFH .
JOURNAL OF CARDIOVASCULAR RISK, 2003, 10 (02) :121-128
[9]
Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity [J].
Guerre-Millo, M ;
Gervois, P ;
Raspé, E ;
Madsen, L ;
Poulain, P ;
Derudas, B ;
Herbert, JM ;
Winegar, DA ;
Willson, TM ;
Fruchart, JC ;
Berge, RK ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16638-16642
[10]
Myopathy and rhabdomyolysis with lipid-lowering drugs [J].
Hodel, C .
TOXICOLOGY LETTERS, 2002, 128 (1-3) :159-168